 MINNEAPOLIS--BUSINESS WIRE--DiaMedica Therapeutics Inc. Nasdaq: DMAC today announced that the last participant has been enrolled and is on treatment in the diabetic kidney disease Cohort of the Companys Phase 2 REDUX chronic kidney disease CKD study. The Company also announced that enrollment has reached 50 in the IgA Nephropathy and African Americans cohorts. DiaMedicas Phase 2 REDUX Latin for restore study is a multi-center, open-label, investigation to assess the safety and effica 